U.S. markets open in 8 hours 8 minutes
  • S&P Futures

    3,613.50
    -23.00 (-0.63%)
     
  • Dow Futures

    29,654.00
    -220.00 (-0.74%)
     
  • Nasdaq Futures

    12,223.50
    -34.00 (-0.28%)
     
  • Russell 2000 Futures

    1,835.50
    -17.50 (-0.94%)
     
  • Crude Oil

    44.67
    -0.86 (-1.89%)
     
  • Gold

    1,773.40
    -14.70 (-0.82%)
     
  • Silver

    22.15
    -0.40 (-1.79%)
     
  • EUR/USD

    1.1977
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    0.8420
    0.0000 (0.00%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3342
    +0.0028 (+0.21%)
     
  • USD/JPY

    103.8820
    -0.2030 (-0.20%)
     
  • BTC-USD

    18,488.07
    -44.81 (-0.24%)
     
  • CMC Crypto 200

    364.32
    +26.83 (+7.95%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,433.62
    -211.09 (-0.79%)
     

Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference

Oncocyte Corporation
·1 min read

IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Piper Sandler Virtual Healthcare Conference on Tuesday, December 1, 2020.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. TheraSure is a trademark of Chronix Biomedical, Inc.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation